Memorial Sloan Kettering Cancer Center’s Y-mAbs Therapeutics YMAB Stock Holding History

Memorial Sloan Kettering Cancer Center’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.04M	Hold	191,176	–	–	4.24%	3
2023 Q2	$1.3M	Hold	191,176	–	–	4.1%	4
2023 Q1	$958K	Hold	191,176	–	–	2.94%	5
2022 Q4	$933K	Hold	191,176	–	–	3.08%	5
2022 Q3	$2.76M	Hold	191,176	–	–	9.37%	3
2022 Q2	$2.89M	Hold	191,176	–	–	9.56%	3
2022 Q1	$2.27M	Hold	191,176	–	–	2.63%	6
2021 Q4	$3.1M	Sell	191,176 -25,740	-12%	-$550K	1.95%	6
2021 Q3	$6.19M	Hold	216,916	–	–	3.86%	6
2021 Q2	$7.33M	Hold	216,916	–	–	4.79%	4
2021 Q1	$6.56M	Hold	216,916	–	–	4.04%	4
2020 Q4	$10.7M	Buy	+216,916	New	+$10M	4.55%	4

Other funds holding YMAB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Memorial Sloan Kettering Cancer Center's YMAB Position: Q3 2023 in Review

Memorial Sloan Kettering Cancer Center held its Y-mAbs Therapeutics (YMAB) position steady in Q3 2023 at 191,176 shares worth $1.04M. The position accounts for 4.24% of the portfolio, ranked #3.

Memorial Sloan Kettering Cancer Center first reported a position in YMAB in Q4 2020 and has held it in 12 quarters since. The position peaked at $10.7M in Q4 2020. 98 funds tracked by Wall St. Rank hold YMAB as of Q3 2023.

Memorial Sloan Kettering Cancer Center held 191,176 shares of Y-mAbs Therapeutics worth $1.04M as of Q3 2023.
Memorial Sloan Kettering Cancer Center left its Y-mAbs Therapeutics share count unchanged in Q3 2023.
Y-mAbs Therapeutics made up 4.24% of Memorial Sloan Kettering Cancer Center's portfolio in Q3 2023, its #3 holding.
Memorial Sloan Kettering Cancer Center first reported a position in Y-mAbs Therapeutics in Q4 2020 and has held it in 12 quarters since.
Memorial Sloan Kettering Cancer Center's Y-mAbs Therapeutics position peaked at $10.7M in Q4 2020.
98 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2023.

Based on Memorial Sloan Kettering Cancer Center's 13F filing for Q3 2023, filed 14 Nov 2023.